• Profile
Close

Methadone, buprenorphine, or detoxification for management of perinatal opioid use disorder: A cost-effectiveness analysis

Obstetrics and Gynecology Nov 03, 2019

Premkumar A, et al. - Researchers compared the cost-effectiveness of methadone, buprenorphine, or detoxification treatment in the management of opioid use disorder (OUD) during pregnancy via creating a decision-analytic model. Using the existing literature, they determined probabilities, costs, and utilities. Calculation of incremental cost-effective ratios for each strategy was done, and cost-effectiveness was defined using a ratio of $100,000 per quality-adjusted life-years. They performed one-way sensitivity analyses and a Monte Carlo probabilistic sensitivity analysis. Findings revealed that under most circumstances, buprenorphine is estimated to be a cost-effective strategy when compared with either methadone or detoxification as a treatment for OUD during pregnancy. Nonetheless, the cost-efficacy of buprenorphine was not observed in almost one out of three simulations, indicating possibly limited robustness of the model and the necessity for further evaluation of the cost-effective approach to the management of OUD during pregnancy.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay